The present invention is directed to a compound of formula I:
or any stereoisomeric form of the compound of the formula I or a mixture of these forms in any ratio or a physiologically acceptable salt of the compound of the formula I which inhibit the enzyme TAFIa (activated thrombin-activatable fibrinolysis inhibitor), and to a process for their preparation and to their use to treat described diseases where the substituents are as described in the specification.
本发明涉及公式I的化合物,或公式I的任何立体异构体形式,或这些形式的任意比例混合物,或公式I的生理上可接受的盐,这些化合物抑制酶TAFIa(活化凝血酶活化的纤溶
抑制剂),以及它们的制备方法和用于治疗所述疾病的用途,其中取代基如说明书所述。